Summary & Overview
HCPCS Q2050: Doxorubicin Hydrochloride, Liposomal, 10 mg
HCPCS Level II code Q2050 denotes an injectable, liposomal formulation of doxorubicin hydrochloride measured per 10 mg. As a specialty chemotherapy agent, this code is used to report supply of the drug unit for systemic anticancer treatment, commonly administered in outpatient infusion centers and physician office infusion suites. Nationally, accurate coding for specialty oncology agents affects clinical documentation, drug inventory control, and payer coverage determinations for high-cost therapies.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code and clinical context, typical sites of service, and which payers are included in the comparative coverage discussion. The publication also summarizes common billing modifiers and operational considerations relevant to reporting high-cost injectable oncology drugs, plus benchmarking and policy considerations where available. Content is aimed at billing managers, oncology clinicians, and revenue cycle staff seeking a national perspective on use and reporting of liposomal doxorubicin units.
Billing Code Overview
HCPCS Level II code Q2050 represents an injection of doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg. This code describes a chemotherapy drug administration by vial/unit of a liposomal formulation of doxorubicin intended for systemic anticancer therapy.
-
Service type: Injectable chemotherapy agent supplied in 10 mg increments for infusion
-
Typical site of service: Hospital outpatient infusion center or physician office infusion suite
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic or recurrent ovarian cancer, Kaposi sarcoma, or other solid tumors for which liposomal doxorubicin is indicated. The patient presents to an oncology infusion center for chemotherapy administration. Prior to treatment, the oncologist confirms diagnosis, reviews prior therapy and cumulative anthracycline dose, verifies cardiac function (e.g., recent echocardiogram or MUGA), confirms vascular access (peripheral IV or implanted port), and obtains informed consent. On the day of service the chemotherapy regimen is prepared by pharmacy using Q2050 (doxorubicin hydrochloride, liposomal, 10 mg unit) and dosed per body surface area or fixed dosing in the chemotherapy order. The infusion nurse performs baseline vital signs, verifies allergies and pre-medication orders, administers pre-medications if required, and infuses the liposomal doxorubicin through the appropriate venous access with standard monitoring for infusion reactions and cumulative cardiotoxicity. Post-infusion nursing documents drug lot, units administered, and any acute reactions. Billing captures the product as Q2050 with appropriate HCPCS modifiers to indicate aspects such as service location, anesthesia involvement, drug wasted, or patient status. Typical site of service is an outpatient hospital-based or freestanding oncology infusion center; this product may also be administered in an inpatient hospital setting when clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|